Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:SYK

Stryker Corp. (SYK)

307.00
-0.80 (0.26%)
as of Jun 18, 2026, 8:52:16 pm Market Open.
184 watching
0
BUY
They don't have the patent cliffs that the drugs are going to come off, and they will continue to innovate. Aging demographics will help demand. He's happy to hold this.
BUY
One of his favourite medtech names. They lead in robotic surgery. Great organic growth. They're setting up for a great quarter.
BUY
The medical device sector has been a leading group for the last three years and he has been a big proponent. They are interesting because it is secular growth. Demographics support what these companies are doing. They are very defensible because they are not tied to the economic cycle. So long as growth performs well, he likes this group. He owns it through the medical devices ETF.
PAST TOP PICK
(A Top Pick Aug 17/18, Up 20%) Hips and knees. Robots doing knee surgery. 3D replacements for hips. Continues to chug along. Growing revenue 6-7%.
TOP PICK

Medical devices in a great demographic growth area. They are developing robotics to assist in surgery. Think of it as a med-tech company. Yield 1.1% (Analysts’ price target is $201.12)

TOP PICK
Medical devices company. Great company. Will continue to grow with the aging population. 73% of the business in the U.S., 23% in Europe and the rest emerging markets. Can grow their business internationally. Very little debt. Great story, great growth and operating margins. (Analysts’ price target is $201.12)
PAST TOP PICK
(A Top Pick Mar 21/18, Up 17%) Fantastic company in diverse medical devices. Leader in hip and knee replacements. Latest quarter was fantastic.
BUY
Great company, trading cheap in the low-20's. It will do well as its competitors stumble.
BUY
A great company that makes medical devices and does hip replacements. A surgeon that uses their equipment won't suddenly switch to another brand; the doctor will stay with Stryker. A problem is that sometimes the FDA approves medical devices too quickly--though that isn't a problem with Stryker. This is a good long-term hold.
BUY ON WEAKNESS
The valuation is about a 10-15% premium to the market. It has predictable growth and has done quite well. They have distinguished themselves in the way they can execute. He prefers this one to others in the space. He would be interested at a lower price.
HOLD
Earnings in last quarter had 6-7% organic growth, 2-3 times better than the competition. Not cheap at 23x earnings. Has differentiated itself from the others in its industry. As long as dividends are growing at a hefty rate, no reason to sell.
BUY
A great medical tech company making equipment for knee replacements and spines. SYK spends a lot of time training doctors to use their equipment, which is not interchangeable with other manufacturers, so those doctors will continue to use SKY equipment. Demographics as society ages help SYK. Well-run, and it hit new highs today. This is a great story. Will do well long-term.
BUY
They do knee and hip replacements. SYK are active in tuck-in acquisitions which is quite accretive. They trade at a decent valuation. A consistent stock performer.
TOP PICK
Has grown its dividend 12% compounded over 5 years. A great international growth story in medical devices. They continue to invest in new technology. They're gaining market share. They're using robots to speed up operations with fewer problems. (Analysts’ price target is $190.40)
TOP PICK
His focus on healthcare equipment. Demographically positive. They make artificial knees and hips, and have introduced robots. Has held in well in market uncertainty. Will be developing more and more technologies. Yield is 1.1%. (Analysts’ price target is $185.27)
Showing 76 to 90 of 146 entries